Showing 2,421 - 2,440 results of 2,687 for search '"chemotherapy"', query time: 0.05s Refine Results
  1. 2421

    Prognosis conferred by molecular features of appendix-derived Pseudomyxoma Peritonei by Ruiqing Ma, Guojun Li, Yingjiang Ye, Lei Liang, Chong Wang, Haipeng Zhou, Pu Zhang, Lubiao An, Guanjun Shi, Qian Chen, Hongbin Xu, Zhidong Gao

    Published 2025-03-01
    “…We investigated the prognostic value for response to cytoreductive surgery (CRS) or hyperthermic intraperitoneal chemotherapy (HIPEC) and dissected potential beneficial targeted therapy utilizing genomic characteristics. …”
    Get full text
    Article
  2. 2422

    Prediksi Interaksi Drug Target pada Gen Kanker Menggunakan Metode Lasso-XGBoost by Muh Fadhil Al-Haaq Ginoga, Wisnu Ananta Kusuma, Mushthofa Mushthofa

    Published 2023-07-01
    “…Abstract Currently, cancer treatment is usually done with chemotherapy using chemical drugs that can cause side effects. …”
    Get full text
    Article
  3. 2423

    The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer by Julie Tsu-Yu Wu, June Corrigan, Chloe Su, Clark Dumontier, Jennifer La, Aparjita Khan, Shipra Arya, Alex H. S. Harris, Leah Backhus, Millie Das, Nhan V. Do, Mary T. Brophy, Summer S. Han, Michael Kelley, Nathanael R. Fillmore

    Published 2024-07-01
    “…Intensive treatment was defined as concurrent use of platinum-doublet chemotherapy and/or dual checkpoint blockade and non-intensive as ICI monotherapy. …”
    Get full text
    Article
  4. 2424

    A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients by Eleni-Kyriaki Vetsika, Filippos Koinis, Marianthi Gioulbasani, Despoina Aggouraki, Anna Koutoulaki, Eirini Skalidaki, Dimitris Mavroudis, Vassilis Georgoulias, Athanasios Kotsakis

    Published 2014-01-01
    “…The percentages and correlation between MDSCs and distinct immune cells in the peripheral blood of 110 chemotherapy-naive patients before treatment and healthy controls were investigated using flow cytometry. …”
    Get full text
    Article
  5. 2425

    Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis by Yi-Zi Zheng, Jia-Qi Ying, Ting-Ting Wu, Yong-Hui Su, Ou-Chen Wang

    Published 2025-02-01
    “…Methods: Women diagnosed with T1cN0M0-stage TNBC who received chemotherapy and surgery were selected from the Surveillance, Epidemiology and End Results database (2010–2020). …”
    Get full text
    Article
  6. 2426

    Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib by Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Manon Reda, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Henri Talucier, Clementine Jankowski, Charles Coutant, Laurent Arnould, Sandrine Dabakuyo

    Published 2025-02-01
    “…Node-negative patients who would have been eligible for adjuvant ribociclib represent 10.9% of the eligible population. 21.7% of patients now eligible for adjuvant abemaciclib, and 32.1% for ribociclib did not receive (neo)adjuvant chemotherapy. After a median follow-up of 144.7 months, 10-year overall survival confirms the prognostic relevance of the inclusion criteria used in pivotal trials. …”
    Get full text
    Article
  7. 2427

    Personalized treatment strategies for breast adenoid cystic carcinoma: A machine learning approach by Sakhr Alshwayyat, Mahmoud Bashar Abu Al Hawa, Mustafa Alshwayyat, Tala Abdulsalam Alshwayyat, Siya sawan, Ghaith Heilat, Hanan M. Hammouri, Sara Mheid, Batool Al Shweiat, Hamdah Hanifa

    Published 2025-02-01
    “…The 5-year overall survival (OS) rates were highest for surgery + radiotherapy (RT) (94.9 %) and lowest for surgery + chemotherapy (CTX) + RT (80.1 %). Positive estrogen receptor (ER) status and younger age were associated with better survival outcomes. …”
    Get full text
    Article
  8. 2428

    A Nomogram Built on Clinical Factors and CT Attenuation Scores for Predicting Treatment Response of Acute Myeloid Leukemia Patients by Linna Liu, Wenzheng Lu, Li Xiong, Han Qi, Robert Peter Gale, Bin Yin

    Published 2025-01-01
    “…<b>Methods</b>: This retrospective study included 74 newly diagnosed AML patients who underwent unenhanced abdominal CT scans within one week before receiving their first induction chemotherapy. Clinical biomarkers of tumor burden were also collected. …”
    Get full text
    Article
  9. 2429
  10. 2430

    Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML by Petra Bašová, Lubomír Minařík, Lubomír Minařík, Silvia Carina Magalhaes-Novais, Jana Balounová, Zuzana Zemanová, Tatiana Aghová, Martin Špaček, Anna Jonášová, Kristýna Gloc Pimková, Jan Procházka, Radislav Sedláček, Tomáš Stopka, Tomáš Stopka

    Published 2025-01-01
    “…IntroductionProgressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN) for intensive chemotherapy ineligible patients. Mouse models that engraft primary AML samples may further advance VEN + AZA resistance research.MethodsWe generated a set of transplantable murine PDX models from MDS/AML patients who developed resistance to VEN + AZA and compared the differences in hematopoiesis of the PDX models with primary bone marrow samples at the genetic level. …”
    Get full text
    Article
  11. 2431

    Composition analysis and mechanism of Guizhi Fuling capsule in anti-cisplatin-resistant ovarian cancer by Lei Dou, Yan Yan, Enting Lu, Fangmei Li, Dongli Tian, Lei Deng, Xue Zhang, Rongjin Zhang, Yin Li, Yi Zhang, Ye Sun

    Published 2025-02-01
    “…Objective: Cisplatin is the main chemotherapy drug for advanced ovarian cancer, but drug resistance often occurs. …”
    Get full text
    Article
  12. 2432
  13. 2433

    Identification of SETD4 as an Onco‐Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers by Yuyun Zhong, Ruiqi Wang, Zijie Huang, Zhaoting Hu, Bin Peng, Bin Chen, Liyue Sun

    Published 2025-01-01
    “…Furthermore, we investigated its association with cancer‐related pathways, the immune microenvironment, immunotherapy markers, and drug resistance signatures of chemotherapy. Additionally, qRT‐PCR was performed to validate SETD4 expression in clinical specimens. …”
    Get full text
    Article
  14. 2434

    Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices by Asmaa M. Zahran, Helal F. Hetta, Zeinab Albadry M. Zahran, Alaa Rashad, Amal Rayan, Dalia O. Mohamed, Zeinab Ahmed Abd Elhameed, Salah M. Khallaf, Gaber El-Saber Batiha, Yasir Waheed, Khalid Muhammad, Hanaa Nafady-Hego

    Published 2021-01-01
    “…We recruited 40 cases of advanced NSCLC, stages III and IV, aged>18–<70 years old, and eligible to receive chemotherapy with or without radiotherapy, along with 20 healthy controls of comparable age and sex; after diagnosis and staging of patients, blood samples were collected for flow cytometric detection of Mo-MDSCs. …”
    Get full text
    Article
  15. 2435
  16. 2436

    Outcomes of oncologic arthroplasty in children and adolescents with malignant limb tumors: a systematic review by Vyacheslav I. Zorin, Sergei V. Vissarionov, Alexandr Y. Makarov, Timofey S. Rybinskikh, Kristina N. Rodionova

    Published 2024-12-01
    “…However, the development and refinement of chemotherapy and radiotherapy protocols, along with advances in surgical techniques and implants, have significantly altered the treatment landscape for these patients. …”
    Get full text
    Article
  17. 2437

    The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration by Chiara Cencioni, Silvia Malatesta, Virginia Vigiano Benedetti, Valerio Licursi, Livia Perfetto, Federica Conte, Danilo Ranieri, Armando Bartolazzi, Martina Kunkl, Loretta Tuosto, Alberto Larghi, Geny Piro, Antonio Agostini, Giampaolo Tortora, Vincenzo Corbo, Carmine Carbone, Francesco Spallotta

    Published 2025-01-01
    “…Methods PDAC development upon dysmetabolic conditions was investigated in: 1) high fat diet fed wild type immunocompetent syngeneic mice by orthotopic transplantation of pancreatic intraepithelial neoplasia (PanIN) organoids; and 2) primary pancreatic CAFs isolated from chemotherapy naïve PDAC patients with/without an history of metabolic syndrome. …”
    Get full text
    Article
  18. 2438

    DNA vaccines as promising immuno-therapeutics against cancer: a new insight by Alireza Shariati, Arya Khezrpour, Fatemeh Shariati, Hamed Afkhami, Hamed Afkhami, Hamed Afkhami, Aref Yarahmadi, Sajad Alavimanesh, Sajad Alavimanesh, Sina Kamrani, Mohammad Hossein Modarressi, Pouria Khani

    Published 2025-01-01
    “…Several approaches including structural modification, combination therapy with conventional and novel cancer treatments (such as chemotherapy, radiotherapy, and immune checkpoint blockade (ICB)), and the incorporation of adjuvants into the plasmid structure have been studied to enhance the vaccine’s immunogenicity and improve the clinical outcome of cancer patients. …”
    Get full text
    Article
  19. 2439

    Exploring the anti-inflammatory effects of phytochemicals in attenuating interstitial cystitis-a literature review by Irfan Anjum, Ayesha Nasir, Faiza Naseer, Faiza Naseer, Ahsan Ibrahim, Bisma Rehman, Fawad Bashir, Qura Tul Ain

    Published 2025-02-01
    “…Hemorrhagic cystitis is a common manifestation in patients undergoing chemotherapy with cyclophosphamide and related alkylating agents. …”
    Get full text
    Article
  20. 2440

    Testicular Cancer Presenting as Gastric Variceal Hemorrhage by Carlos Eduardo Salazar-Mejía, David Hernández-Barajas, Edio Llerena-Hernández, José Luis González-Vela, María Inés Contreras-Salcido, Adriana González-Gutiérrez, Omar David Borjas-Almaguer, Luis Alberto Pérez-Arredondo, Blanca Otilia Wimer-Castillo

    Published 2017-01-01
    “…A CT scan showed extrinsic compression of the portal vein by lymphadenopathy along with splenic vein partial thrombosis, which caused left-sided portal hypertension. Neoadjuvant chemotherapy was started with etoposide and cisplatin, and seven days later the patient underwent left radical orchiectomy. …”
    Get full text
    Article